Entity

Time filter

Source Type

North Sydney, Australia

Pang J.H.,Australian National University | Pang J.H.,Sirtex Medical Ltd | Coupland L.A.,Australian National University | Coupland L.A.,Clinical Haematology Unit | And 3 more authors.
Clinical and Experimental Metastasis | Year: 2015

The promotion of tumour metastasis by platelets may occur through several mechanisms including the induction of a more metastatic phenotype in tumour cells and assisted extravasation of circulating tumour cells. Whilst the mechanisms underlying platelet-assisted extravasation have been extensively studied, much less attention has been paid to the mechanisms underlying platelet promotion of an aggressive phenotype within a tumour cell population. Herein, we demonstrate in vitro that MDA-MB-231 breast carcinoma cells incubated with washed thrombin-activated platelet membranes adopt a Matrigel-degrading phenotype in a dose- and contact time-dependent manner. The same phenotypic change was observed with three other human tumour cell lines of diverse anatomical origin. Moreover, tumour cell lines that had been cultured with washed thrombin-activated platelet membranes had a greater metastatic capacity when injected into mice. This in vivo effect was reliant upon a co-incubation period of >2 h implying a mechanism involving more than platelet membrane binding that occurred within 5 min. Upon further investigation it was found that simultaneous blocking of the platelet-membrane proteins P-selectin and GPIIb/IIIa prevented interactions between platelet membranes and MDA-MB-231 cells but also significantly reduced the ability of tumour cells to degrade Matrigel. These results confirm that platelets induce a more aggressive phenotype in tumour cells but also identify the platelet proteins involved in this effect. P-selectin and GPIIb/IIIa also play a role in assisting tumour cell extravasation and, thus, are ideal targets for the therapeutic intervention of both stages of platelet-assisted metastasis. © 2015, Springer Science+Business Media Dordrecht. Source


Jain N.,University of Sydney | Wang Y.,University of Sydney | Jones S.K.,Sirtex Medical Ltd | Hawkett B.S.,University of Sydney | Warr G.G.,University of Sydney
Langmuir | Year: 2010

The preparation and properties of an aqueous ferrofluid consisting of a concentrated (>65 wt %) dispersion of sterically stabilized superparamagnetic, iron oxide (maghemite) nanoparticles stable for several months at high ionic strength and over a broad pH range is described. The 6-8 nm diameter nanoparticles are individually coated with a short poly(acrylic acid)-b-poly(acrylamide) copolymer, designed to form the thinnest possible steric stabilizing layer while remaining strongly attached to the iron oxide surface over a wide range of nanoparticle concentrations. Thermogravimetric analysis yields an iron oxide content of 76 wt % in the dried particles, consistent with a dry polymer coating of approximately 1 nm in thickness, while the poly(acrylamide) chain length indicated by electrospray mass spectrometry is consistent with the 4-5 nm increase in the hydrodynamic radius observed by light scattering when the poly(acrylamide) stabilizing chains are solvated. Saturation magnetization experiments indicate nonmagnetic surface layers resulting from the strong chemical attachment of the poly(acrylic acid) block to the particle surface, also observed by Fourier transform infrared spectroscopy. © 2010 American Chemical Society. Source


Trademark
Sirtex Medical Ltd | Date: 2012-12-04

Pharmaceutical preparations for the treatment of cancer; biological preparations for medical and veterinary purposes, namely, for the treatment of cancer; capsules and particles in the nature of radio-isotopes, radionuclides, chemotherapeutic agents and magnetic materials for medical and pharmaceutical purposes for the treatment of cancer; chemical preparations for medical and pharmaceutical purposes for the treatment of cancer; chemical preparations for veterinary purposes for the treatment of cancer; drugs for medical purposes for the treatment of cancer; microcapsules for the treatment of cancer; microscopic particles in the nature of radio-isotopes, radionuclides, chemotherapeutic agents and magnetic materials containing radioactive material for medical therapeutic use for the treatment of cancer; microcapsules containing pharmaceutical, veterinary or medical preparations for the treatment of cancer; microcapsules and microparticles in the nature of radio-isotopes, radionuclides, chemotherapeutic agents and magnetic materials adapted to selectively deliver material, including radioactive materials, chemical agents and heat, to a target site such as a cell or organ for the treatment of cancer; microscopic particles in the nature of radio-isotopes, radionuclides, chemotherapeutic agents and magnetic materials and microcapsules for the treatment of cancer; microscopic particles in the nature of radio-isotopes, radionuclides, chemotherapeutic agents and magnetic materials adapted to selectively deliver material, including radioactive materials, chemical agents and heat, to a target site such as a cell or organ for the treatment of cancer. Medical research; scientific research for medical purposes; research and development of medical and veterinary products for medical and veterinary purposes, including pharmaceuticals, microcapsules, microparticles, radioactive materials, chemical agents and preparations, cancer treatments and treatments for diseased cells; medical and scientific research relating to molecular sciences, pharmaceuticals, drugs, chemicals and biotechnology.


Patent
Sirtex Medical Ltd | Date: 2015-07-07

Accordingly, the present invention provides a method of treating lung neoplasia in a subject in need of treatment, by subjecting the patient to SIRT.


Patent
Sirtex Medical Ltd | Date: 2013-08-16

The invention relates to a particulate material having a diameter in the range of from 5 to 200 microns comprising polymeric matrix and stably incorporated radionuclide, processes for its production and a method of radiation therapy utilising the particulate material.

Discover hidden collaborations